26 February 2016 - Alprolix would be among the first therapies in the EU to offer people living with hemophilia B prolonged protection against bleeding episodes with prophylactic dosing intervals.

For more details, go to: http://media.biogen.com/press-release/biosimilars/sobi-and-biogen-receive-positive-opinion-chmp-alprolix-rfixfc-treatment-he